Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Multiple Ascending Dose Phase 1/1B Pharmacokinetic and Pharmacodynamic Study of STM 434, an Activin Type 2B Receptor Fc Fusion, Alone and in Combination with Liposomal Doxorubicin in Patients with Ovarian Cancer or Other Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

An Open-Label Multiple Ascending Dose Phase 1/1B Pharmacokinetic and Pharmacodynamic Study of STM 434, an Activin Type 2B Receptor Fc Fusion, Alone and in Combination with Liposomal Doxorubicin in Patients with Ovarian Cancer or Other Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STM 434 (Primary) ; Doxorubicin liposomal
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Atara Biotherapeutics

    • Most Recent Events

    • 08 May 2019 Results published in the Clinical Cancer Research
    • 10 Feb 2017 Status changed from recruiting to completed.
    • 08 Aug 2016 According to an Atara Biotherapeutics media release, the company plans to begin the monotherapy dose expansion component of this trial by the end of 2016 in patients with advanced granulosa cell or clear cell ovarian cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top